Advertisment

Vtama Cream 1% Shows Promising Results for Plaque Psoriasis in Adults - Phase 4 Study Results

author-image
Mason Walker
New Update
NULL

Vtama Cream 1% Shows Promising Results for Plaque Psoriasis in Adults - Phase 4 Study Results

Advertisment

Impressive Results in Phase 4 Clinical Trial

Advertisment

Dermavant Sciences, a forward-thinking biopharmaceutical company, has released the results of their Open Label Phase 4 Clinical Trial for Vtama cream, a promising treatment for plaque psoriasis in the head and neck region for adults. The results were overwhelmingly positive, demonstrating strong efficacy, with 88.5% of adult patients achieving a target lesion Physician's Global Assessment (PGA) success score of 0 (clear) or 1 (almost clear) and a 2-grade improvement from their baseline condition by week 12.

Rapid Onset of Efficacy

Another noteworthy aspect of the trial's results was the rapid onset of efficacy. The median time for patients to achieve clearance was a mere four weeks. This quick response time is an encouraging sign for patients suffering from plaque psoriasis, a chronic skin condition characterized by patches of abnormal skin, who are often in need of swift relief.

Advertisment

Complete Clearance and Significant Improvement

By the end of the 12-week study, a staggering 80.8% of adult patients had achieved complete clearance of the target lesion. Furthermore, an impressive 96.2% of patients achieved a 75% improvement in the Psoriasis Area and Severity Index (PASI 75) of the head and neck region. The PASI is a tool used for the measurement of severity and extent of psoriasis, and a 75% improvement is a significant indicator of the treatment's efficacy.

Well-Tolerated with No New Safety Concerns

Advertisment

Throughout the course of the trial, the Vtama cream was well-tolerated by the patients. The most common adverse reactions reported were folliculitis, contact dermatitis, headache sinusitis, and seborrheic keratosis. Importantly, no new safety signals were observed during the 12 weeks of the trial.

Effective Treatment for Scalp Psoriasis

The results from the phase 4 trial are particularly promising for those suffering from scalp psoriasis in the head and neck region. The efficacy, safety, and tolerability of Vtama cream could make it a leading choice for topical treatment for this often difficult-to-treat area.

Conclusion: A Promising Step Forward

The successful results of Dermavant's Phase 4 trial for Vtama cream mark an exciting step forward in the treatment of plaque psoriasis. The strong efficacy, rapid onset of results, and high rate of complete clearance, coupled with its safety and tolerability, make Vtama cream a potentially transformative treatment for adults suffering from plaque psoriasis in the head and neck region. As more studies are conducted and more data becomes available, the potential for Vtama cream to improve the lives of psoriasis patients continues to grow.

Advertisment
Chat with Dr. Medriva !